Who We Are

Ciana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies within ophthalmology and with an initial focus on Diabetic Retinopathy.

Read more

Unmet Need

More than 463 million patients are living with diabetes. A serious complication of diabetes is Diabetic Retinopathy.

Diabetic Retinopathy damages the eyes in patients with diabetes and can lead to vision loss and blindness. This eye complication afflicts 125 million patients with diabetes globally – and 30 million people in the US and Europe alone.

Read more

Novel Approach

Ciana’s therapy is based on Danegaptide – a drug that can both treat Diabetic Retinopathy and prevent disease progression.

Unlike the leading injectable eye therapies that only block VEGF and limit vascular edema, Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.

Read more

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Facts on Diabetic Retinopathy

Better treatments are needed to prevent vision loss and blindness

Patient Focused

Combatting vision loss and blindness in patients with diabetes

NormalDiabetic Retinopathy
NormalDiabetic Macular Edema
Drag bar  : See Normal versus Disease

Work with us

Developing a front-line treatment to combat vision loss and blindness in diabetes

CONTACT US